治療用血漿交換市場-世界の産業規模、シェア、動向、機会、および予測、2018～2028年、製品別、技術別、適応症別、エンドユーザー別、地域別、競合

世界の治療用血漿交換市場は、2022年に7億6,201万米ドルの評価額に達し、予測期間中に堅調な成長が見込まれ、年間平均成長率（CAGR）は6.75%と予測され、2028年には11億1,160万米ドルに達する見込みです。

主な市場促進要因

• 1.神経疾患、腎疾患、血液疾患の高い有病率：腎疾患、急性肝不全、ギラン・バレー症候群（GBS）などを含む慢性疾患の有病率の高さが、治療用血漿交換市場全体の成長に寄与しています。治療用血漿交換の応用が急増しており、他の治療法と比較してその有効性を評価するための集中的な研究や臨床試験が行われています。これらの要因は治療用血漿交換市場の成長を大きく後押ししています。
• 2.治療用血漿交換の研究開発の進歩：連続流遠心分離のような高精度技術が特定の血液成分を効果的に分離し、次世代アフェレシス装置の開発を含む技術的進歩が観察されています。先進的なTPEシステムは、手作業の介入を最小限に抑え、手技の効率を向上させ、幅広い病態への採用を促進します。
• 3.治療用血漿交換の応用範囲の拡大：広範な神経疾患の治療が、マーケット成長の重要な触媒となっています。TPEは、急性炎症性脱髄性多発神経炎、重症筋無力症（MG）、腫瘍随伴性脳症などの疾患の一次治療と考えられています。さらに、その他のさまざまな神経疾患の二次治療としても使用されています。これらの神経疾患の有病率は上昇を続けており、市場の進展に寄与しています。
• 4.バイオ医薬品企業による原血漿の需要増加：さまざまな衰弱性疾患、慢性疾患、生命を脅かす疾患の治療のために、生物製薬会社から供給される血漿の需要が増加していることは、大きな推進力となっています。血漿由来の治療法は、広範な疾患の治療において重要な役割を果たしており、血漿由来製品の需要とプラズマフェレーシス市場の成長に寄与しています。

主な市場課題

• 1.プラズマフェレーシス手技に伴うリスク：プラズマフェレーシスの手順では、人体から血液の一部を取り出し、補充液を静脈内に投与します。一般的に安全と考えられているが、感染、アレルギー反応、低血圧、内出血、電解質不均衡などを含む関連リスクがあります。これらのリスクは、プラズマフェレーシスの普及を制限する可能性があります。
• 2.治療用血漿交換製剤の高コスト：アフェレーシス装置や使い捨て部品のような治療用血漿交換に必要な特殊装置のコストが、この手技の高コストの一因となっています。品質管理プロセスや業界標準への準拠がさらにコストに拍車をかけています。TPE製品の生産規模が限られていることも、単位あたりのコスト上昇につながります。

主な市場動向：

• 1.絶え間ない進歩：継続的な技術進歩により、患者の満足度が向上し、血液由来製品の処理が改善されます。連続流遠心法のような先進的な方法は、最小限の血流しか必要としないため、採血を容易にする上でより先進的です。このような技術開発が市場開拓の機会を生み出しています。
• 2.小児用途における治療用血漿手順の使用：治療用血漿交換療法は、さまざまな疾患における病原性物質の除去において、小児への応用がますます研究されています。これには小児の希少疾患や自己免疫疾患の治療も含まれ、市場の成長に寄与しています。

セグメント別洞察

• 1.適応症別洞察：神経疾患は、高齢者人口におけるこれらの疾患の発生率と有病率の増加、およびこの分野での継続的な調査により、市場を独占すると予想されます。
• 2.技術別洞察：遠心分離技術は、ドナーアフェレーシスにおいて広く採用され、費用対効果と効率的な血漿除去を提供することから、治療用血漿交換市場で大きなシェアを占めると予測されます。

地域別洞察：

北米は世界の治療用血漿交換市場を独占しており、自己免疫疾患の高い有病率、確立された病院インフラ、バイオテクノロジー企業の強い存在感などの要因がその成長に寄与しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の治療用血漿交換市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（消耗品、デバイス）
  • 技術別（遠心分離、膜分離）
  • 適応症別（神経疾患、血液疾患、腎疾患、代謝疾患、その他）
  • エンドユーザー別（採血センター・血液成分プロバイダー、病院・クリニック、輸血センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 北米の治療用血漿交換市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の治療用血漿交換市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の治療用血漿交換市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の治療用血漿交換市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカ治療用血漿交換市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 世界の治療用血漿交換市場のSWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Therapeutic Plasma Exchange Market reached a valuation of USD 762.01 Million in 2022 and is expected to experience robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.75% and expected to reach USD 1111.60 Million through 2028.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an advanced medical procedure used to separate pathogenic substances from patients' blood and replace them with replacement fluids, such as albumin solution or fresh frozen plasma. These substances include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is widely employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing significantly to market expansion. It also offers the significant benefit of reducing plasma viscosity and is utilized in the management of chronic diseases as a first-line or second-line therapy or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers:

• 1. High Prevalence of Neurological, Renal, and Hematological Disorders: The high prevalence of chronic diseases, including nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. There has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.

• 2. Advances in Therapeutic Plasma Exchange Research and Development: High-precision technologies like continuous-flow centrifugation effectively separate specific blood components, and technological advancements, including the development of next-generation apheresis devices, are being observed. Advanced TPE systems minimize manual intervention, enhance procedure efficiency, and promote the adoption of such systems for a wide range of conditions.

• 3. Expanding Variety of Therapeutic Plasma Exchange Applications: The treatment of a wide array of neurological disorders serves as a significant catalyst for market growth. TPE is considered the primary treatment for conditions such as acute inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Additionally, it is employed as a secondary treatment for various other neurological conditions. The prevalence of these neurological disorders continues to rise, contributing to market progress.

• 4. Increasing Demand for Source Plasma from Biopharmaceutical Companies: The growing demand for source plasma from biopharmaceutical companies for the treatment of various debilitating, chronic, and life-threatening disorders is a significant driver. Plasma-derived therapies play a crucial role in the treatment of a broad spectrum of diseases, contributing to the demand for plasma-derived products and the growth of the plasmapheresis market.

Key Market Challenges:

• 1. Risk Associated with Plasmapheresis Procedures: Plasmapheresis procedures involve extracting a portion of blood from the human body and administering replacement fluids intravenously. While generally considered safe, there are associated risks, including infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. These risks may limit the widespread adoption of plasmapheresis.

• 2. High Cost of Therapeutic Plasma Exchange Products: The cost of specialized equipment required for therapeutic plasma exchange, such as apheresis machines and disposable components, contributes to the high cost of the procedure. Quality control processes and compliance with industry standards further add to the cost. The limited scale of production for TPE products can also lead to higher per-unit costs.

Key Market Trends:

• 1. Continuous Advancement: Ongoing technological advancements enhance patient satisfaction and improve the processing of blood-derived goods. Advanced methods like continuous-flow centrifugation require minimal blood flow, making them more advanced for facilitating blood collection. These technological developments create opportunities within the market.

• 2. Use of Therapeutic Plasma Procedure in Pediatric Applications: Therapeutic plasma exchange treatments are increasingly studied for pediatric applications in the removal of pathogenic materials in various diseases. This includes the treatment of rare pediatric disorders and autoimmune diseases, contributing to market growth.

Segmental Insights:

• 1. Indication Insights: Neurological disorders are expected to dominate the market, driven by the increasing incidence and prevalence of these diseases in the geriatric population and ongoing research in this field.

• 2. Technology Insights: Centrifugation technology is projected to hold a significant share in the Therapeutic Plasma Exchange market, thanks to its widespread adoption in donor apheresis, offering cost-effectiveness and efficient plasma removal.

Regional Insights:

North America dominates the global therapeutic plasma exchange market, with factors such as a high prevalence of autoimmune diseases, a well-established hospital infrastructure, and a strong presence of biotech enterprises contributing to its growth.

Key Market Players

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutic Plasma Exchange Market, By Product:

• Consumables
• Devices

Therapeutic Plasma Exchange Market, By Technology:

• Centrifugation
• Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

• Neurological Disorders
• Haematology Disorders
• Renal Disorders
• Metabolic Disorders
• Others

Therapeutic Plasma Exchange Market, By End User:

• Blood Collection Centres & Blood Component Providers
• Hospitals & Clinics
• Blood Transfusion Centres
• Others

Therapeutic Plasma Exchange Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

• Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Devices)
  • 5.2.2. By Technology (Centrifugation, Membrane Separation)
  • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
  • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Asahi Kasei Corporation
  • 15.5.2. Baxter International Inc
  • 15.5.3. B. Braun Melsungen AG
  • 15.5.4. Cerus Corporation
  • 15.5.5. Fresenius Kabi AG
  • 15.5.6. Haemonetics Corporation
  • 15.5.7. Hemacare Corporation
  • 15.5.8. IncMedica S.p.A.
  • 15.5.9. Kawasumi Laboratories
  • 15.5.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer